In the first head-to-head study of Rinvoq versus Dupixent in atopic dermatitis, the AbbVie drug showed superiority on a composite endpoint measuring skin clearance and itch resolution.

Seeking to clear up a ‘misconception,’ Oncology Center of Excellence officials say earlier endpoints, such as progression-free survival and overall response, continue to be useful in getting therapies to market quicker, but sponsors still should plan to systematically collect OS data to ensure there is no detriment to survival.

Some patients have already been prescribed the new drug for pulmonary arterial hypertension but Merck & Co. did not provide any sales or guidance. 

AstraZeneca’s CEO says his potential 11% pay rise is needed to help the European industry remain competitive with its higher paying US counterparts.